SLC5A2 and diabetes mellitus: Empagliflozin (EMP) is a newer type of diabetes medication that works by inhibiting the proximal tubular sodium-glucose co-transporter-2 (SGLT-2) and is hence referred to as an SGLT-2 inhibitor [2].